Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WHAT KIND OF SORCERY IS GOING ON HERE.
I GUESS ITS A GOOD THING TO SEE SOMETHING HAPPEN, FINALLY
WTF IS GOING ON
er'we go..
turn'around time...
hopefully it keeps up this way
KALY USMJ OCLN PHOT - Penny Stocks Set to Breakout
Date : 01/08/2019 @ 9:19AM
Source : InvestorsHub NewsWire
Stock : Kali, Inc. (PN) (KALY)
Quote : 0.0229 0.0003 (1.33%) @ 9:37AM
KALY USMJ OCLN PHOT - Penny Stocks Set to Breakout
Print
Alert
HENDERSON, NV -- January 8, 2019 -- InvestorsHub NewsWire -- Sometimes penny and sub-penny stocks can bring savvy traders massive profits in an extremely short period of time. Due to their low price and extreme volatility the price swings can be enormous. While they carry risk, they can supply huge rewards. We've uncovered several penny stocks that could make traders very happy.
One that popped off the screen is OriginClear, Inc. (OCLN) they have a lot more going on than your average penny stock. Trading near its bottom, there is a lot of potential for a parabolic breakout as investors learn about this company.
Today we are highlighting: OriginClear, Inc. (OCLN), SinglePoint, Inc. (SING), North American Cannabis Holdings, Inc. (USMJ), GrowLife, Inc. (PHOT), and Kali, Inc. (KALY).
Water scarcity is becoming a serious problem in the United States. Water quality reports indicate that 45% of U.S. streams, 47% of lakes, and 32% of bays are polluted. Americans use over 2.2 billion pounds of pesticides every year, which eventually washes into our rivers and lakes. Over 73 different kinds of pesticides have been found in U.S. groundwater that eventually ends up in our drinking water. The 5-minute daily shower most Americans take uses more water than a typical person in a developing country uses in a whole day.
OriginClear, Inc. (OCLN) (Market Cap: $1.941M, Share Price: $0.0013) is a leading provider of water treatment solutions. Through its wholly owned subsidiaries, OriginClear provides systems and services to treat water in a wide range of industries, such as municipal, pharmaceutical, semiconductors, industrial, and oil & gas. The company's water treatment solution has been gaining traction in rural areas, and their client list continues to grow. Most sub-penny stocks don't have the kind of fundamentals OCLN does, which makes it especially interesting.
As the company builds its client base it will be an interesting target for potential buyers and/ or partners looking to expand their network. In anticipation of potential M&A activity OCLN recently retained TCA International Group for a range of services including identifying potential merger, acquisition, divestiture, consolidation or other combination opportunities and negotiating, structuring and advising in connection with potential M&A Transactions.
A major announcement could be on the horizon, so now's the time to start your due diligence on OCLN.
____
SinglePoint, Inc. (SING) (Market Cap: $28.107M, Share Price: $0.0237), just announced its investment in TorusMed Inc. to develop CBD Cell Cultures from industrial hemp. Recently the 2018 Farm Bill was passed, opening a vast array of opportunities. SinglePoint plans to quickly acquire and invest in companies dealing directly within the now legalized industrial hemp market.
____
North American Cannabis Holdings, Inc. (USMJ) (Market Cap: N/A, Share Price: $0.0013) released a 2019 New Year message from the CEO and Chairman Steven Rash. Mr. Rash is also the President and Chairman of ACI Conglomerated, the majority shareholder of USMJ.
____
Last month, GrowLife, Inc. (PHOT)(Market Cap: $22.462M, Share Price: $0.0070), an indoor cultivation product and service provider, held its Annual Meeting of Stockholders. At the meeting, more than 90 percent of shares were voted and all items put forward by management were passed by a majority vote.
____
Kali, Inc. (KALY)(Market Cap: $23.012M, Share Price: $0.0226) has an upcoming analyst research report scheduled for publication on Tuesday, January 8th, 2019 to provide shareholders with an extensive market analysis of the company's business plan and progress toward its business plan objects. The analyst report is expected to include detail on KALY's recent $400,000 in new contracts and the $5 million in revenue expected from KALY's hemp farming initiative with Nouveau (NOUV).
Legal Disclaimer:
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to a three-month term consulting agreement with OCLN dated 10/23/18. The agreement calls for $20,000 in cash, and 10,000,000 restricted 144 shares of OCLN per month. OCLN paid an additional $6,000 for an additional news commentary for the first month of service. All payments were made directly by OriginClear, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. OCLN was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communications LLC
KALY - New Report Notes Kali-Extracts, Inc. Has Multiple Shots on Goal in Multi-Billion Dollar MarketsFont size: A | A | A
9:15 AM ET 1/8/19 | GlobeNewswire
KALY - New Report Notes Kali-Extracts, Inc. Has Multiple Shots on Goal in Multi-Billion Dollar Markets
BALTIMORE, Jan. 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Goldman Small Cap Research has issued a new research report on Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY). The report outlines the company's current positioning and potential, upcoming milestones. To read or download the report, along with reading associated disclosures and disclaimers, visit www.GoldmanResearch.com.
Kali Report Highlights
Kali, Inc. is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies to include the licensing of its patented cannabis extraction technology to multiple companies in the wellness and pharmaceutical industries. With promising preclinical data along with development and commercial agreements behind it, Kali-Extracts seeks to commercialize its unique and valuable IP targeting multi-billion dollar markets. The recent legalization of hemp farming in the 2018 Farm Act just signed into law by President Trump puts the wind at Kali's back.
The Company's multi-pronged approach is divided into two target categories: Pharmaceuticals and Wellness.
Goldman highlighted the key segments in his research report.
"In the pharmaceutical space, Kali has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released in 1Q19. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025."
"In the wellness arena, the early affirmation of its extract's efficacy has occurred via sales of Puration Inc.'s CBD-infused product which is based on Kali's IP. Various joint ventures in which Kali has engaged are likely sources of near term revenue for Kali in the CBD-infused product market, projected to grow to $22 billion in the next few years. Plus, these relationships could result in additional business opportunities going forward. All told, Kali believes it could generate $5 million or more in revenue from specific endeavors with current partnerships."
About Goldman Small Cap Research: Founded in 2009by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published report on Kali, Inc. The information provided in the report was for information use only and may have contained forward-looking statements along with statements of fact that may have been obtained from sources considered reliable. Thus, we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from press releases issued by and due diligence related to management of Kali, Inc. some of which are referred to in authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report, we may from time to time include our own opinions about the Companies, its business, markets and opportunities. Any opinions we may offer about the Companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein and in the report may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
It should be noted that Kali has recently updated all of its financial reports required by OTCMarkets to satisfy the OTCMarkets "current" filing standards and anticipates that the OTCMarkets site to soon reflect Kali's "current" filing status. As of the report publication date, OTCMarkets has yet to update this status. All quotation information cited in the report was derived from Yahoo!Finance which reports Kali intraday trading activity and news.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, podcast interview or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download or view the Kali report or any of our research on Puration, Inc., or other sponsored research, please view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com.
Goldman Small Cap Research was compensated $3500 by the Company for the publication of this report. It should be noted that during 2018, GSCR was compensated by Puration, Inc. in the amount of $5500 for a research subscription service and a previous podcast interview.
About Kali, Inc. (OTC - KALY) Kali, Inc. is a health and wellness company set to generate revenue via licensing its patented cannabis extraction technology to multiple companies in the wellness and pharmaceutical industries. With promising preclinical data along with development and various commercial agreements behind it, Kali, Inc. seeks to commercialize its unique and valuable IP targeting multi-billion-dollar markets.
For more information, please visit: www.kali-extracts.com
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
> Dow Jones Newswires
January 08, 2019 09:15 ET (14:15 GMT)
KICK ASS REPORT!!!
GOO $KALY....
KALY - Kali-Extracts Analyst Research Report Featuring New Cannabis Biotechnology Business Set For Release TomorrowFont size: A | A | A
11:55 AM ET 1/7/19 | GlobeNewswire
KALY - Kali-Extracts Analyst Research Report Featuring New Cannabis Biotechnology Business Set For Release Tomorrow
DALLAS, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) ("KALY") today confirmed the previously announced analyst research report featuring the company's new cannabis biotechnology business will be released tomorrow. On November 15th, 2018, KALY acquired NCM Biotech to include a patented cannabis extraction process and associated intellectual properties consisting of years of preclinical research studies surrounding a multitude of applications of cannabis extracts derived from the patented cannabis extraction process. KALY recently published a summary of results of one of many preclinical research studies in order to present an example of the underlying value of Kali-Extracts overall cannabis biotechnology intellectual properties. KALY is currently a partner in US Cannabis Health with Puration, Inc. (USOTC: PURA) and Nouveau (USOTC: NOUV) which has signed an LOI to explore the development of cannabis therapies in partnership with Generex Biotechnology (OTCQB: GNBT). The analyst report is also expected to include detail on KALY's recent $400,000 in new contracts and the $5 million in revenue expected from KALY's hemp farming initiative with NOUV. KALY has recently updated all its financial reports required by OTCMarkets to satisfy the OTCMarkets "current" filing standards and anticipates the OTCMarkets site to soon reflect KALY's "current" filing status. The analyst research report scheduled for publication tomorrow on Tuesday, January 8(th) , 2019 is intended to augment the OTCMarkets requirements by providing shareholders with an extensive market analysis of the company's new business plan and progress toward its new business plan objects.
To learn more about the KALY visit www.kali-extracts.com.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
USMJ CEO 2019 New Year Msg Outlining $20 M Revenue Goal for USMJ Family of Companies - PURA KALY PJET NOUV
Date : 01/04/2019 @ 9:18AM
Source : InvestorsHub NewsWire
Stock : North American Cannabis Holdings, Inc. (PC) (USMJ)
Quote : 0.0014 0.0001 (7.69%) @ 9:42AM
USMJ CEO 2019 New Year Msg Outlining $20 M Revenue Goal for USMJ Family of Companies - PURA KALY PJET NOUV
Print
Alert
Dallas, TX -- January 4, 2019 -- InvestorsHub NewsWire -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) today released a 2019 New Year message from the CEO and Chairman Steven Rash. Mr. Rash is also the President and Chairman of ACI Conglomerated, the majority shareholder of USMJ. His letter, included below in its entirety, provides an update on pending key events for USMJ and the USMJ family of companies to include, Puration, Inc. (USOTC: PURA) (“PURA”), Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY), Nouveau Life Pharmaceuticals, Inc. (dba/Nouveau) (USOTC: NOUV) and Priority One Aviation (Pending Name Change)(USOTC: PJET)(“PJET”). ACI Conglomerated is the majority shareholder of all of the USMJ family of companies except for KALY. KALY is part of the family through contract. PURA has licensed KALY’s patented cannabis extraction process for the production of cannabis infused beverages and PURA and KALY are partners in a joint venture with NOUV called US Cannabis Health. Combined, with a specific by company breakout included in the letter below, the USMJ family of companies have an initial revenue goal totaling $20 million. As some of the companies in the family of companies have not yet set revenue goals, the total goal is expected to increase by the end of the first quarter. Read more below:
Dear Shareholders –
Let me start by wishing all a Happy New Year. I consider 2018 to have been a great year for the USMJ family of companies and I anticipate 2019 to be a pivotal year for the US cannabis industry at large and in turn, a tremendous year for USMJ, PURA, KALY, NOUV and PJET.
As I have noted in a previous communication, the legalization of hemp farming in the United States under the 2018 Farm Act is the biggest thing yet to happen to the cannabis sector world-wide and potentially the biggest event that will ever happen in the cannabis sector. On behalf of all our companies, I’m excited about the prospects of having US domestic hemp for the production of CBD. This will be a watershed event for KALY and PURA.
Even knowing the CBD aspect of legal hemp farming is a watershed event for KALY and PURA, I also know that legal hemp farming is much, much bigger than just CBD production. I am not understating anything when I tell you that hemp farming will have a massive economic impact worldwide, not just in the agriculture sector, but across the entire global economy. Legal hemp farming in the US will permeate through the pharmaceutical sector, the construction sector, the fashion sector and the energy sector to name just a few. Hemp farming is anticipated to generate $50,000 per acre and with NOUV launching its first 100 acres of hemp this year, you could see NOUV ringing $5 million in revenue in 2019.
While legal hemp farming, in my opinion, is the biggest event that will ever happen to the cannabis sector, I anticipate another cannabis sector event will get rolling this year that garners even more media attention than hemp farming. As 2019 winds down toward the 2020 Presidential Election, I anticipate we will see President Trump push for the legalization of recreational marijuana as part of his campaign. Between hemp farming and the likely advance toward the legalization of recreational marijuana, I expect 2019 to be a huge year for established entrepreneurial cannabis sector companies. I believe “USMJ” will become one of the most notable brand names in the cannabis sector.
So, with all the enthusiasm I can muster, Happy New Year to all. USMJ’s revenue goal for its soon to be launched ecommerce site is $10 million. PURA’s cannabis beverage sales goal is $5 million. KALY and NOUV anticipate $5 million in sales form their combined efforts with the 100-acre hemp farm. PJET has not yet set a revenue goal for its new AmeriCanna Cafe business and KALY and NOUV have not set individual revenue goals separate from their combined hemp farming initiative. In addition to the $20 million in combined sales goals for the USMJ family of companies, USMJ shareholders will soon be receiving a dividend of PJET stock, and PURA shareholders will soon be receiving a dividend of NOUV stock. The dividend issuance is taking a little longer than anticipated but is still on track. KALY has recently updated all its financial reports required by OTCMarkets and anticipates the OTCMarkets site to soon reflect KALY’s current filing status. KALY also anticipates publishing an analyst research report on Tuesday, January 8th, 2019 to provide shareholders with an extensive market analysis of the company’s business plan and progress toward its business plan objects.
Please keep a lookout on OTCMarkets and each of the companies’ websites for the latest updates in what we expect to be a very exciting 2019.
Sincerely,
Steven Rash
CEO and Chairman
USMJ and ACI Conglomerated
www.growusmj.com
www.purationinc.com
www.kali-extracts.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Steven Rash
CEO North American Cannabis Holdings, Inc.
info@aciconglomerated.com
+1-800-861-1350
Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
Date : 01/03/2019 @ 3:04PM
Source : InvestorsHub NewsWire
Stock : Kali, Inc. (PN) (KALY)
Quote : 0.0209 -0.0023 (-9.91%) @ 3:25PM
Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
Print
Alert
Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen Wound Healing Collagen Matrix
Collagen Solutions & Berkshire Sterile Manufacturing to Supply Excellagen for Q1 Launch
MIRAMAR, FL -- January 3, 2019 -- InvestorsHub NewsWire -- Generex Biotechnology Corporation (GNBT) today announced that its partially, soon to be fully-owned subsidiary, Olaregen Therapeutix, Inc. has signed critical manufacturing agreements for Excellagen with Collagen Solutions, a highly-regarded supplier of medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine applications, and with Berkshire Sterile Manufacturing (BSM), a state-of-the art, GMP fill/finish manufacturer providing formulation and sterile filling as well as analytical development and stability services to the biotech and pharmaceutical industries. The two contract manufacturers will produce and package Excellagen in two dose formulations for the initial product launch in the first quarter of 2019, with a third dosage option for large wounds to follow shortly thereafter.
The wound care market is expected to reach $22.8 billion by 2023 from roughly $19 billion in 2018 at a compounded annual growth rate of 3.7%, according to a report from Markets & Markets. Advanced wound care products are designed to cure and treat a variety of complex wounds, such as diabetic foot ulcers, venous ulcers, and pressure ulcers, burn, trauma and other types all of which Excellagen are cleared for use. The rising incidence of difficult to treat wounds are driving the growth of advanced wound healing products resulting from Increasing prevalence of diabetes, a rapidly aging population as well as developments and innovations in enhanced wound care products such as Excellagen.
In the United States, it is estimated that as many as 4.5 million people have chronic wounds, resulting in substantial economic and psychosocial costs. Various pathologic states result in chronic wound development, including arterial or venous insufficiency, diabetes, undue skin pressure, presence of a foreign body, and infection.
Anthony J. Dolisi, CEO of Olaregen Therapeutix commented: "We are extremely pleased to announce the initiation of production of Excellagen and our partnership with Collagen Solutions and BSM. These premier manufacturing companies have the scale and flexibility to ensure that Olaregen is prepared for commercial introduction with multiple dosing options for Excellagen. We now have access to vast resources and customer/support networks with a common goal of reducing waste and allowing vertical markets to select the optimal, cost-effective Excellagen dose based on the patients' needs. Wound healing is clearly a market that needs to address these issues. With a comprehensive understanding of the needs of physicians and patients, combined with a strategy that embraces improved product offerings along with a competitive economic advantage we are confident is our roadmap to success."
Joe Moscato, CEO of Generex said, "We are excited that Olaregen has begun its commercialization efforts for Excellagen in 17 FDA-cleared treatment indications, especially in surgical applications and in areas of high unmet medical need like Mohs surgery (for skin cancer) and diabetic foot ulcers. As we advance the aims of Generex in building a best-in-class regenerative medicine company, I am pleased to announce that Generex has signed a term sheet for a $15 million equity line to make our obligatory payments to fund the manufacturing and commercial launch of Excellagen, and to ultimately close the full acquisition of Olaregen. The equity line, once complete, will also be available to fund the clinical development of Regentys Extra-Cellular Matrix Hydrogel (ECMH) that will culminate in FDA submission and approval. The equity line enables Generex to manage its financials by making payments to our subsidiaries based on value-driven milestones rather than through immediate shareholder dilution. We plan to provide details of this equity financing agreement in the coming days as we finalize the closing documents and receive Generex board approval on the full transaction". Mr. Moscato continued, "The closing documents for Regentys are complete and in attorney review, and that closing should take place in the coming days, followed shortly thereafter by Olagregen. In addition, we will be announcing plans to add two new acquisitions to the NuGenerex family of companies that will add significant revenues to NuGenerex Distribution Solutions."
About Generex Biotechnology
Generex Biotechnology is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development. The mission of the company is to provide physicians, hospitals, and all healthcare providers with an end-to-end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care processes, minimizing expenses, and delivering transparency for payers.
About Olaregen Therapeutics
Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.
About our Service-Disabled Veteran-Owned Small Business (SDVOSB)
This a Service-Disabled Veteran-Owned Small Business (SDVOSB) that specializes in the sale, marketing, and distribution of innovative medical products through a nationwide network of veteran owned distribution services.
About Cannabis Therapies US Cannabis Health LOI
Generex Biotechnology has also stepped forward in the rapidly evolving and growing cannabis based therapies sector entering into an LOI with US Cannabis Health, a JV between Puration, inc. (PURA), Kali-Extracts, Inc. (KALY) and Nouveau Life Pharmaceuticals, Inc. (NOUV). The LOI includes an agreement for KALY to produce specialized CBD extracts for infusion into a bottled water to be produced by PURA under a private label for Generex.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Nice....
$kaly
wasn't the Goldman report supposed to come out this week?
Dang... the one piece of the puzzle we need to get this going.
I feel it will show the true colors of $Kaly
UMM
GOOO $KALY....
it's time to bring $KALY current...
this will be a runner...
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$TGGI $IGPK $GCGX
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$TGGI $IGPK $GCGX
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$TGGI $IGPK $GCGX
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$KALY $NOUV $PJET $WCVC $USMJ
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$KALY $NOUV $PJET $WCVC $USMJ
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$KALY $NOUV $PJET $WCVC $USMJ
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$KALY $NOUV $PJET $WCVC $USMJ
Happy New Year to all shareholders...
May 2019 bring us a lot of Great News, Good Health, Peace, Love and Wealth.
All be safe, have fun, please don't drink & drive and again, Happy New Year 2019
$KALY $NOUV $PJET $WCVC $USMJ
But the buy back has not worked out as planned. So basically they're throwing in the towel and doing a RS
Its logical and the only way to get it up...
Its like VIAGRA. . . The only way to get it up is with a pill... well for us is with a RS
First I'll wait for them to announce it.
Once they do, that'll push some investors to buy and this baby will move one or two ticks or maybe a few, they all do when a RS is announced, then I'll sell
Chant?? It's now in black n white. . . and most likely the only way to get that pps up to uplist
This is now a sinking ship, well chit it's always been a sinking ship, it just now turned to the Titanic...
Run For The HILLLLSSSSSSSSS!!!!!
Exactly...
REVERSE SPLIT COMING!!! RUN FOR THE HILLSSSSSS!!!!
MY GUESS IS, THEY WILL DO A 300 TO 1 RS. . . just to get it above .01, and I think I'm low balling this chit...
Gooo $HAON... down the drain...
will there be another BLOODBATH this afternoon?
I'm ready for the dip
I have etrade and i only have to wait 3 days to re-sell
Looks like they also need a proof-reader before posting anything.
Simple words people. Simple words...
Spelling to me shows the true professional level of an individual or company and they have truly proven to be in a much lower level than expected of a company. Geez....
Now, let us hear some real news and move this pps.
looking forward to it
HE'S BABYSITTING THE NEWS...
The FARM BILL SIGNING has BEGUN
go $KALY $PJET $NOUV $PURA
The FARM BILL SIGNING has BEGUN
go $KALY $PJET $NOUV $PURA
USMJ - North American Cannabis Holdings Plans To Make USMJ a Billion-Dollar Brand Name In 2019
Date : 12/20/2018 @ 5:35PM
Source : InvestorsHub NewsWire
Stock : Priority Aviation, Inc. (PN) (PJET)
Quote : 0.0058 -0.0007 (-10.77%) @ 2:45PM
USMJ - North American Cannabis Holdings Plans To Make USMJ a Billion-Dollar Brand Name In 2019
Print
Alert
USMJ - North American Cannabis Holdings Plans To Make USMJ a Billion-Dollar Brand Name In 2019
Farmers Branch, TX -- December 20, 2018 -- InvestorsHub NewsWire -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) today released an online update on the imminent launch of the company’s Amazon of Cannabis E-commerce site and plans to build the “USMJ” name into a billion-dollar brand name in 2019. USMJ recently spun-off its AmeriCanna Cafe business to Priority Aviation, Inc. (USOTC: PJET) (“PJET”) with the intent of issuing PJET common stock to the shareholders of USMJ in a dividend distribution as a component of the spin-off transaction. The intent remains the same and the update includes the latest progress toward that end. PJET plans to soon change its corporate name in conjunction with the new business direction. PJET has entered into an agreement with West Coast Venture Group (OTCQB: WCVC) (“WCVC”) to roll out the AmeriCanna Cafe concept restaurant in Colorado in the Spring of 2019 where USMJ, PJET and WCVC all co-participate in an AmeriCanna Cafe marketing campaign. The onset of that marketing campaign is a 2019 Miss USMJ Calendar to go on sale any minute now. Miss USMJ Calendar Mary Jane Girls will participate via social media and live events in conjunction with the AmeriCanna Cafe rollout marketing campaign. Today, USMJ is a million dollars in annual sales cannabis logistics company supporting various cannabis enterprises that expects to leverage its logistics background to dramatically expand its new E-commerce business and substantially grow its revenue in 2019. The update narrative is included in its entirety below in addition being available on the company’s website at www.growusmj.com.
USMJ Billion Brand Name and E-Commerce Site
The USMJ warehouse is stocked with products that will be sold on the USMJ E-commerce site. The USMJ E-commerce site is built and ready to launch. The payment engine is in place. All the launch is waiting on now is legal sign-off to make sure the site abides by the rapidly evolving related regulations. We still expect to launch the site before the end of December. We can’t wait. We’re all so excited and think the market will be to.
The site is designed to be a source of information on the continually evolving landscape of the cannabis industry in addition to being source of CBD products for people and pets, and a source of products for members of the cannabis lifestyle community. The site will help members of the cannabis lifestyle community find what they’re looking for.
AmeriCanna Cafe Rollout With WCVC
West Coast Ventures Group Corp. (WCVC) develops, owns and operates two contemporary restaurant concepts: Illegal Burger, a quick-casual burger + bar concept, and El Señor Sol, a full-service fresh Mexican restaurant (5 restaurants in the Denver Colorado area). The Company generates gross annual sales of $2,725,000.
Illegal Burger, a subsidiary of West Coast Ventures has partner with AmeriCanna Cafe to pilot a cannabis-themed restaurant in Colorado. The pilot will be launched in the form of a food truck featured in pop-up venues near a series of recreational marijuana dispensaries in Colorado. The pilot rollout is scheduled to start in the spring of 2019.
USMJ will soon introduce the 2019 Miss USMJ Calendar for sale in conjunction with an AmeriCanna Cafe marketing campaign. The 2019 Miss USMJ Calendar Mary Jane Girls will participate in the campaign via social media and live events.
The initial agreement between Illegal Burger and AmeriCanna Cafe does not include any exchange of equity between the two companies or their respective parent companies. Management of both companies indicates a future equity exchange is possible.
PJET Dividend Coming Soon
PJET issued USMJ a $1.5 million convertible note in exchange for the AmeriCanna Cafe business as part of the spin-off transaction. PJET and USMJ are working to promptly convert the $1.5 million note into a number of common PJET shares sufficient to issue one PJET common share for every fifty shares of USMJ common shares issued and outstanding. All of the PJET common shares issued in conversion of the purchase note are slated for distributed to USMJ shareholders in a dividend distribution. Prior to issuing the PJET dividend, PJET plans to have its past-due reports required by OTCMarkets updated prior to the issuance of the dividend. The reports are all updated, and the posting of the reports is imminent. PJET expects to have all reports updated and the dividend issued very soon with the target remaining to be complete before year end. Holiday schedules of all the various entities required to complete all of the above is a concern, but PJET management is pushing forward.
USMJ 2019 $10 Million Sales Goals
USMJ has a consistent base of business that management anticipates will continue in the range of approximately $1 million per year. Without having yet launched the E-commerce site, management is hesitant to voice its sales goals and set expectations too high or too low. Having offered our precautions regarding our sales goals, we are conservatively expecting to double our sales in the next calendar year and we are setting a goal or sales goal on reaching a annual sales rate of $10 million a year from now.
www.growusmj.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Steven Rash
CEO North American Cannabis Holdings, Inc.
info@aciconglomerated.com
+1-800-861-1350
how does L2 look
doubled up on my shares on another dip...
truly ready to play with $PJET
BAM!!! got mine on the dip... and now ready to play with PJET...
Bring on the multi-pennies...
GOOO $PJET
yeah, i put in an order already at .0065 but wondering if I should drop it a bit, who knows, maybe a quick dip in the am
what's your take on pps at opening bell tomorrow?
Anyone???
ready to come in and play with $PJET